Document is current
Any future updates will be listed below
-
Authors
Barbanti, Piero https://orcid.org/0000-0002-5670-3755
Aurilia, Cinzia
Torelli, Paola
Egeo, Gabriella
d’Onofrio, Florindo
Finocchi, Cinzia
Carnevale, Antonio
Viticchi, Giovanna
Russo, Marco
Quintana, Simone
Orlando, Bianca
Fiorentini, Giulia
Messina, Roberta
Bartolini, Marco
Pistoia, Francesca
Filippi, Massimo
Bonassi, Stefano
Cevoli, Sabina
Mannocci, Alice
,
-
Funding
Funding for this research was provided by:
This work was partially supported by the Italian Ministry of Health (Institutional Funding Ricerca Corrente) IRCCS San Raffaele Roma and by Fondazione Italiana Cefalee (FICEF).
- License Information
-
More Information
Article History
Received: 8 December 2024
Revised: 8 January 2025
Accepted: 11 January 2025
First Online: 25 January 2025
Declarations
:
: Piero Barbanti reports personal compensation for consulting, serving on a scientific advisory board, speaking, research support, collaborated for clinical trials, or other activities with Abbvie, Alder, Allergan, Amgen, Angelini, Assosalute, Bayer, Biohaven, DOC Pharma, Eli-Lilly, Fondazione Ricerca e Salute, GSK, Lundbeck, Noema Pharma, Organon, Pfizer, Teva, Viatris, Visufarma, and Zambon, and serves as President with Italian Association of Headache Sufferers. Cinzia Aurilia received travel grants from Eli-Lilly, FB-Health, Lusofarmaco, and Teva, and honoraria from Novartis, Eli-Lilly, and Teva; Paola Torelli received travel grant, honoraria as a speaker, or for participating in advisory boards from Novartis, Teva, Eli Lilly, and Allergan; Gabriella Egeo received travel grants and honoraria from Eli-Lilly, Novartis, New Penta, and Ecupharma; Florindo d’Onofrio received travel grant, honoraria as a speaker or for partecipating in advisory boards from Novartis, Teva, Neopharmed Gentili, Qbgroup srl, K link srl, and Eli-Lilly; Cinzia Finocchi received grants and honoraria from Novartis, Eli Lilly, TEVA, and AIM group; Giovanna Viticchi received honoraria for speaker activities and participating in advisory boards from Eli-lilly, AbbVie, Teva, and Boehringer Ingelheim; Marco Russo received travel grants and honoraria as a speaker or for participating in expert panels from Eli Lilly, Abbvie, and Lundbeck; Simone Quintana received travel grants and honoraria as a speaker or for participating in expert panels from Eli Lilly, Abbvie, and Pfizer; Roberta Messina received honoraria for speaker activities and participating in advisory boards from Abbvie, Biomedia, Eli Lilly, Lundbeck, Organon, Pfizer, and Teva; Marco Bartolini received honoraria for speaker activities from Lusofarmaco and Neopharmed; Massimo Filippi is the Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology; received compensation for consulting services from Alexion, Almirall, Biogen, Horizon, Merck, Novartis, Roche, and Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Horizon, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Horizon, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, and Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, and Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA); Sabina Cevoli received honoraria for speaker panels from Teva and Novartis; Antonio Carnevale, Bianca Orlando, Giulia Fiorentini, Francesca Pistoia, Stefano Bonassi, and Alice Mannocci have no disclosures to declare.
